In 2013, the US Preventive Services Task Force (USPSTF) reaffirmed its prior recommendation to screen all pregnant persons for HIV infection (A recommendation), based on evidence that screening accurately detects HIV infection during pregnancy, and that interventions-in particular antiretroviral therapy (ART)-are associated with marked reduction in risk of mother-to-child transmission. The purpose of this evidence report was to update the 2012 USPSTF review 5, 6 on the benefits and harms of prenatal screening for HIV infection, focusing on previously identified research gaps: direct evidence on benefits and harms of screening vs no screening, optimal frequency of screening, and benefits and long-term harms of currently recommended ART regimens.
Methods

Scope of Review
Detailed methods and additional study details and results on congenital abnormalities are available in the full evidence report at https://www.uspreventiveservicestaskforce.org/Page/Document/ UpdateSummaryFinal/human-immunodeficiency-virus-hivinfection-screening1. Key studies are highlighted in this manuscript. Figure 1 shows the analytic framework and key questions (KQs) that guided the review.
Data Sources and Searches
The Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews and Ovid MEDLINE were searched from 2012 through June 2018 (eMethods 1 in the Supplement).
Since June 2018, we continued to conduct ongoing surveillance through article alerts and targeted searches of high-impact journals 
Key questions
What are the benefits of screening for HIV infection in pregnant women on risk of mother-to-child transmission of HIV infection? 1
What are the harms of currently recommended antiretroviral therapy regimens given during pregnancy to the mother and infant? 5
What is the effectiveness of currently recommended antiretroviral therapy regimens for reducing mother-to-child transmission of HIV infection?
4
What is the yield (number of new diagnoses per number of tests performed) of repeat HIV screening at different intervals in pregnant women, and how does the yield of screening vary in different risk groups? to identify major studies published in the interim that may affect the conclusions or understanding of the evidence and therefore the related USPSTF recommendation. The last surveillance was conducted on January 25, 2019, and identified no relevant new studies. Searches were supplemented with expert suggestions and by reviewing reference lists from relevant systematic reviews and prior USPSTF reports.
Study Selection
Two investigators independently reviewed titles, abstracts, and full-text articles using predefined eligibility criteria. Randomized clinical trials (RCTs), cohort studies, and case-control studies of pregnant adolescents (13 to <18 years) and adults were eligible for all KQs. 
Data Abstraction and Quality Rating
For each study, one investigator abstracted information on populations, interventions or screening instruments, comparators, outcomes, study designs, and settings. A second investigator reviewed abstractions for accuracy. Two independent investigators assessed the quality of each study as good, fair, or poor using predefined criteria developed by the USPSTF (eMethods 2 in the Supplement). 8 Quality ratings for individual studies are provided in eTables 1 and 2 in the Supplement.
Data Synthesis
Results were summarized qualitatively. Meta-analysis was not performed because of clinical and methodological heterogeneity among studies. For all KQs, the overall strength of the body of evidence was assessed as high, moderate, low, or insufficient using methods developed by the USPSTF, based on quality of studies, consistency of results between studies, precision of estimates, study limitations, and risk of reporting bias. The applicability of the findings to US primary care populations and settings was also assessed.
Results
Two reviewers independently assessed 1232 unique citations and 162 full-text articles for inclusion ( Figure 2 ). Twenty-nine new studies in 36 articles were included (2 trials in 2 articles 9, 10 and 27 cohort studies in 34 articles Table 2 ) evaluated associations with combination ART during pregnancy on rates of mother-to-child transmission.
Results were consistent with the findings from the prior review, with mother-to-child transmission rates as low as less than 1% with full-course combination ART. New evidence found that 1 cohort study evaluated infants (n = 4459) born between 1996 and 2010 in 7 European cohorts who were at high risk of acquiring HIV infection (mother with viral load >50 copies/mL in the last 8 weeks of pregnancy, only received intrapartum ART, or received no antenatal or intrapartum ART). 16 Most regimens were protease inhibitor-based triple therapy (82.5%). The rate of mother-to-child HIV transmission was highest in women who initiated ART during the third trimester and in whom viral loads nearest delivery were detectable (4.4% [95% CI, 2.1%-7.9%]). There were no instances of HIV transmission among 2651 women who started ART before pregnancy, continued ART throughout pregnancy, and had a viral load less than 50 copies/mL at the time of delivery.
Two smaller cohort studies, 1 from Canada 25 (n = 645) and 1 from the United Kingdom and Ireland 39 (n = 2406) reported rates of mother-to-child HIV transmission with combination ART of 1% and 0.5%, respectively. In the United Kingdom/Ireland study, ritonavirboosted lopinavir was associated with a higher transmission rate when ART was initiated during the third trimester (1.9%). 39 An Israeli cohort study 28 (n = 796) found combination ART during pregnancy associated with decreased risk of vertical transmission (adjusted OR, 0.4 [95% CI, 0.1-0.8]); transmission rates were 1.5% with vaginal delivery and 0.6% with cesarean delivery. Results were not stratified by timing of ART administration.
One new, fair-quality RCT, the Promoting Maternal and Infant Survival Everywhere (PROMISE) trial (n = 3490), 9 was conducted in India and Africa among HIV-infected women (92% breastfeeding) with CD4 cell counts of or greater than 350/mm 3 at 14 weeks' or later gestation ( Table 2 ). The rate of mother-to-child transmission was 1.8% with zidovudine alone, 0.5% with ART with zidovudine, lamivudine, and lopinavir/ritonavir, and 0.6% with ART with tenofovir, emtricitabine, and lopinavir/ritonavir (difference in rate for combined ART regimens vs zidovudine alone, −1.3% [95% CI, −2.1% to −0.4%]).
Harms of Treatment
Key Question 5. What are the harms of currently recommended ART regimens given during pregnancy to the mother and infant?
Birth Outcomes
The 2012 Abbreviations: AOR, adjusted odds ratio; ART, antiretroviral therapy; HAART, highly active antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase inhibitor; NR, not reported; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. a All studies were rated fair quality. The prior review 5 found no consistent evidence of an association between maternal exposure to ART and increased risk of other adverse birth outcomes (eg, low birth weight, small for gestational age). New evidence identified for this update also found mixed evidence on these birth outcomes. Four new cohort studies 21, 27, 31, 34 evaluated the association of ART with risk of low birth weight.
Overall Congenital Abnormalities
The 2012 USPSTF review found no association between perinatal exposure to ART and overall congenital abnormalities, based on 3 cohort studies (n = 13 396 
Cardiovascular Congenital Anomalies
The 2012 USPSTF review included 1 cohort study 60 (n = 382) that found no significant association between in utero exposure to zidovudine and abnormalities in left ventricular structure or function, although another study 61 found an association between in utero ART and echocardiographic findings with unknown clinical significance in children up to age 2 years. One subsequent RCT and 2 cohort studies (in 3 publications) also reported mixed results for the association between in utero ART exposure and adverse cardiovascular findings. A nested RCT within a cohort study of combination ART (zidovudine, lamivudine, and ritonavir-boosted lopinavir) vs protease inhibitor monotherapy (ritonavir-boosted lopinavir alone) performed echocardiographic assessments at ages 1 month (n = 53) and 1 year (n = 42). There was no significant difference in echocardiographic parameters in boys, but in girls combination therapy was associated with higher left ventricular shortening fraction at 1 month (−3.61 [95% CI, −6.57 to −0.65], P = .02). 35 
Neurodevelopmental Outcomes in Children
The 2012 USPSTF review included 3 cohort studies (n = 4779) that found no significant association between in utero exposure to ART and long-term adverse effects on child growth and development. 54, 58, 68 Two new publications of a US cohort of HIVexposed, uninfected children found no significant association between in utero ART exposure and lower scores on intelligence tests. 29, 42 Exposure to tenofovir was associated with higher scores on the Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III) test than no exposure to tenofovir (WPPSI-III performance IQ scores, 100.8 vs 96.1; P = .03). Another publication from this study found in utero exposure to combination ART associated with less neurodevelopmental impairment vs no exposure (adjusted relative risk, 0.47 [95% CI, 0.27-0.83]). In the PROMISE trial (n = 3490; see KQ4 for study details), 9 antenatal zidovudine-based combination ART was associated with a higher rate of maternal grade 2 or higher adverse events than zidovudine alone (21% vs 17%, P = .008). There was no increased risk in all-cause mortality, anemia, or diabetes among ART regimens. 80 There were few study withdrawals attributable to adverse events.
Discussion
As in previous USPSTF reviews, 6, 81 there remains no direct evidence on effects of prenatal screening vs no screening on risk of mother-to-child HIV transmission or maternal or infant clinical outcomes, or the yield of repeat or alternative screening strategies. review that combination ART is highly effective at reducing the risk of mother-to-child transmission, with some cohort studies reporting rates of mother-to-child transmission of less than 1% when started early in pregnancy. 26, 39 New evidence on harms of ART was also largely consistent with the 2012 USPSTF review. Evidence from primarily observational studies found prenatal combination ART with a boosted protease inhibitor associated with increased risk of preterm delivery. 9,19,37,43 For other birth outcomes (low birth weight, small for gestational age, stillbirth, birth defects, neonatal death), results were mixed and depended on the specific antiretroviral drug or drug regimen given and timing of prenatal therapy. Preferred drug regimens in pregnancy are frequently revised as drugs are developed and safety data become available.
Limitations
This review had several limitations. First, inclusion was restricted to English-language articles, although no non-English language articles that would have met inclusion criteria were identified. Second, meta-analysis was not possible because of differences in study designs, populations, study setting, antiretroviral regimens evaluated, and outcomes. Because pooling was not performed, it was also not possible to formally assess for publication bias with graphical or statistical methods. Third, observational studies, which are more susceptible to bias and confounding than well-conducted RCTs, were included, although inclusion was restricted to observational studies that performed statistical adjustment for potential confounding. Fourth, RCTs of combination ART have only been conducted in Africa, which could reduce their applicability to US practice because of differences in the antiretroviral drugs evaluated, delayed initiation of ART, inclusion of women who breastfeed, and other factors. Fifth, most studies reported results for individual ART agents and classes rather than for ART regimens as a whole, making it difficult to apply findings to currently recommended regimens.
Conclusions
Combination ART was highly effective at reducing risk of motherto-child HIV transmission. Use of certain ART regimens during pregnancy was associated with increased risk of harms that may be mitigated by selection of ART regimen. The 2012 review found that avoidance of breastfeeding and cesarean delivery in women with viremia also reduced risk of transmission and that prenatal screening accurately diagnosed HIV infection.
